Cardioprotective effects of a novel designer C-type natriuretic peptide-based therapeutic, C53 , for the prevention of post-myocardial infarction heart failure

26 August 2018 (10:05 - 10:55)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Mr Yang Chen

Mayo Clinic, Rochester (United States of America)

6 More presentations in this session

Presentation thumbnail

Feasibility and efficacy of early donepezil with or without metoprolol in reperfused myocardial infarction rats

Doctor M. Li (Osaka, JP)

Abstract Slides

Presentation thumbnail

The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist

Doctor P. Kolkhof (Wuppertal, DE)

Abstract Slides

Presentation thumbnail

Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat

Doctor H. Yip (Kaohsiung, TW)

Abstract Slides

Presentation thumbnail

Empagliflozin improves left ventricular diastolic function in db/db mice without altering cardiac expression of enzymes relevant for ketone body or branched chain amino acid catabolism.

Miss J. Moellmann (Aachen, DE)

Presentation thumbnail

Empagliflozin prevention of heart failure development in diabetes is associated with an improvement in cardiac energy producition

Professor S. Verma (Toronto, CA)

Abstract Slides

Access the full session

Session thumbnail

Targeting reverse remodelling in heart failure

The Event

ESC Congress 2018

26 August 2018 10:05 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Presentation

Audience Q&A

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources